Publication | Open Access
Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
240
Citations
22
References
2016
Year
Drug survival was superior for ustekinumab compared with infliximab, adalimumab and etanercept in patients with psoriasis.
| Year | Citations | |
|---|---|---|
Page 1
Page 1